Get the Stockscreener App
1.53
0.00%
0.00
Aclaris Therapeutics Inc stock is traded at $1.53, with a volume of 1.09M.
It is up +0.00% in the last 24 hours and up +8.51% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.53
Open:
$1.52
24h Volume:
1.09M
Relative Volume:
1.04
Market Cap:
$165.67M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-2.9423
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
-10.00%
1M Performance:
+8.51%
6M Performance:
-38.31%
1Y Performance:
+15.91%
1-Day Range:
$1.50
$1.59
1-Week Range:
$1.46
$1.8594
52-Week Range:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.53 | 165.67M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
How many analysts rate Aclaris Therapeutics Inc. as a “Buy”Breakout Stocks Signals For Fast Growth - jammulinksnews.com
How volatile is Aclaris Therapeutics Inc. stock compared to the marketBreakout Stocks Watchlist That Work - jammulinksnews.com
Is it the right time to buy Aclaris Therapeutics Inc. stockDaily Trading Report For Consistent Profits - jammulinksnews.com
Is Aclaris Therapeutics Inc. stock bottoming outTechnical Screener for High Growth Stocks - Newser
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
Is a relief rally coming for Aclaris Therapeutics Inc. holdersTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Aclaris Therapeutics Inc. outperform the marketRisk Shielded Trade Watch with Analysis - Newser
What is the dividend policy of Aclaris Therapeutics Inc. stockAdvanced Screener Recommendation For 2025 - jammulinksnews.com
Aclaris Therapeutics Inc. Breaks Below Key Support LevelQuick Gain Stock Watch With Indicators Reviewed - metal.it
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Market reaction to Aclaris Therapeutics Inc.’s recent newsEntry Alert Based on Volume Spikes Detected - metal.it
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus - Benzinga
Momentum divergence signals in Aclaris Therapeutics Inc. chartAI Model Forecasting Reversal and Breakout Zones - Newser
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga
Aclaris Therapeutics Announces Positive Top-Line Results - GlobeNewswire
Aclaris Therapeutics stock soars after positive Phase 2a trial results By Investing.com - Investing.com South Africa
Aclaris Therapeutics stock soars after positive Phase 2a trial results - Investing.com Australia
Aclaris Therapeutics Announces Positive Phase 2a Trial Results - TipRanks
Aclaris reports positive results from ATI-2138 atopic dermatitis trial By Investing.com - Investing.com South Africa
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - GlobeNewswire
Breakthrough in Atopic Dermatitis: New Drug ATI-2138 Achieves 77% Improvement in Phase 2a Trial - Stock Titan
Aclaris Therapeutics Inc. At Decision Level — Rebound or ResistanceSmart Investment Tips Gaining Popularity Among Analysts - metal.it
What makes Aclaris Therapeutics Inc. stock price move sharplyBuy Opportunity Forecast for Fast Traders - Newser
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionLong-Term Trend Tracking and Signal Summary - Newser
Biopharma firm with big St. Louis operations names new chief scientific officer - The Business Journals
What are Aclaris Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - jammulinksnews.com
Aclaris Therapeutics Announces Leadership Transition - GlobeNewswire
Aclaris Appoints Drug Development Veteran Behind 6 FDA-Approved Antibodies as New CSO - Stock Titan
What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsOutstanding capital returns - jammulinksnews.com
Using R and stats models for Aclaris Therapeutics Inc. forecasting Free Smart Trend Trading with Weekly Signals - Newser
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockHigh-performance stocks for savvy investors - jammulinksnews.com
How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsFree High-Accuracy Stock Picks - metal.it
What are the latest earnings results for Aclaris Therapeutics Inc.Capitalize on emerging growth stocks - jammulinksnews.com
Published on: 2025-07-28 01:01:49 - jammulinksnews.com
Published on: 2025-07-27 19:20:18 - jammulinksnews.com
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser
What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com
What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):